litlas
Log inCreate account

Maggie C.U. Cheang

Active 2004–2024

76
Papers
32,482
Citations
59
h-index
76
i10-index

Citations

Citations per year for Maggie C.U. Cheang1990: 1 citations1994: 2 citations1997: 1 citations1998: 1 citations2004: 2 citations2005: 44 citations2006: 87 citations2007: 144 citations2008: 232 citations2009: 248 citations2010: 422 citations2011: 432 citations2012: 377 citations2013: 424 citations2014: 405 citations2015: 419 citations2016: 426 citations2017: 391 citations2018: 388 citations2019: 1,133 citations2020: 1,154 citations2021: 1,048 citations2022: 745 citations2023: 548 citations2024: 778 citations2025: 377 citations2026: 24 citations1991–1993: no citations, so these years are not shown1995–1996: no citations, so these years are not shown1999–2003: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,540 citing papers, 26.7% of this breakdownChina: 1,319 citing papers, 9.9% of this breakdownUnited Kingdom: 893 citing papers, 6.7% of this breakdownItaly: 651 citing papers, 4.9% of this breakdownCanada: 579 citing papers, 4.4% of this breakdownGermany: 525 citing papers, 4% of this breakdownSpain: 465 citing papers, 3.5% of this breakdownFrance: 445 citing papers, 3.3% of this breakdownAustralia: 396 citing papers, 3% of this breakdownJapan: 295 citing papers, 2.2% of this breakdownNetherlands: 286 citing papers, 2.2% of this breakdownSouth Korea: 284 citing papers, 2.1% of this breakdown
0%26.7%Other 27.1%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology52.2%
  • Medicine39.7%
  • Computer Science2.9%
  • Immunology and Microbiology2.4%
  • Engineering0.5%
  • Chemistry0.4%
  • Other1.9%

Topics

  • Breast Cancer Treatment Studies10.1%
  • Cancer Genomics and Diagnostics5.5%
  • HER2/EGFR in Cancer Research5%
  • Cancer Cells and Metastasis4.6%
  • Advanced Breast Cancer Therapies3.1%
  • Breast Lesions and Carcinomas2.8%
  • Other68.9%

Coauthors

All papers

Open in search
  1. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

    Authors: Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang, Samuel Leung, David Voduc, Tammi L. Vickery, Sherri R. Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu, John F. Quackenbush, Inge J. Stijleman, Juan Palazzo, J. S. Marron, Andrew B. Nobel, Elaine R. Mardis, Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. Bernard - Journal of Clinical Oncology 2009 cited by 4,887

  2. Metastatic Behavior of Breast Cancer Subtypes

    Authors: Hagen F. Kennecke, Rinat Yerushalmi, Ryan Woods, Maggie C.U. Cheang, David Voduc, Caroline Speers, Torsten O. Nielsen, Karen A. Gelmon - Journal of Clinical Oncology 2010 cited by 2,284

  3. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

    Authors: Isaac García-Murillas, Gaia Schiavon, Britta Weigelt, Charlotte K.Y. Ng, Sarah Hrebien, Rosalind Cutts, Maggie C.U. Cheang, Peter Osin, Ashutosh Nerurkar, Iwanka Kozarewa, Javier Armisen Garrido, Mitch Dowsett, Jorge S. Reis‐Filho, Ian E. Smith, Nicholas C. Turner - Science Translational Medicine 2015 cited by 1,132

  4. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study

    Authors: Maggie C.U. Cheang, Charles M. Perou, Melissa A. Troester, Lisa A. Carey, Robert C. Millikan, Chad Livasy, Lynn G. Dressler, H. Shelton Earp, Torsten O. Nielsen, Sandra L. Deming, C.-K. Tse, Gamze Karaca, Patricia G. Moorman, Joseph Geradts, Kathleen Conway, Sharon N. Edmiston, David Cowan - JAMA 2006 cited by 3,834

  5. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial

    Authors: Sarah E. Pinder, S. Kernaghan, G. Wilson, Andrew Wardley, J.M. Flanagan, M.Q. Hatton, P. Gazinska, R. Brown, K.M. Timms, P. Ellis, Charles M. Perou, R. Roylance, Maggie C.U. Cheang, C. Harper-Wynne, Percy Parker, Peter Barrett‐Lee, I.E. Smith, M. Dowsett, C. Gillett, S. Chan, J.M. Bliss, J. Parikh, Lucy Kilburn, A. Ashworth, J. Owen, M. LL. HARRIES, N. Rahman, J. Abraham, S. Barrett, Katherine A. Hoadley, A. Shaw, H. Tovey, A. Gutin, Vandna Shah, Andrew Tutt, A. Grigoriadis, Levi Fox, J.S. Lanchbury - Nature Medicine 2018 cited by 903

  6. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

    Authors: Maggie C.U. Cheang, Stephen Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri R. Davies, Philip S. Bernard, Joel S. Parker, Charles M. Perou, Matthew J. Ellis, Torsten O. Nielsen - JNCI Journal of the National Cancer Institute 2009 cited by 2,220

  7. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

    Authors: Ian Smith, J.F.R. Robertson, Lucy Kilburn, Maggie Wilcox, Abigail Evans, Chris Holcombe, Kieran Horgan, Cliona Kirwan, Elizabeth Mallon, Mark Sibbering, Anthony Skene, Raghavan Vidya, Maggie C.U. Cheang, Jane Banerji, James P. Morden, Kally Sidhu, Andrew Dodson, Judith M. Bliss, Mitch Dowsett - The Lancet Oncology 2020 cited by 317

  8. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

    Authors: Zuzana Kos, Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen, Koen Van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil Badve, W. Fraser Symmans, Christos Sotiriou, David L. Rimm, Stephen M. Hewitt, Carsten Denkert, Sibylle Loibl, Stephen J. Luen, John M. S. Bartlett, Peter Savas, Giancarlo Pruneri, Deborah Dillon, Maggie C.U. Cheang, Andrew Tutt, Jacqueline A. Hall, Marleen Kok, Hugo M. Horlings, Anant Madabhushi, Jeroen van der Laak, Francesco Ciompi, Anne‐Vibeke Lænkholm, Enrique Bellolio, Tina Gruosso, Stephen B. Fox, Juan Carlos Araya, Giuseppe Floris, Jan Hudeček, Leonie Voorwerk, Andrew H. Beck, J. Kaplan Kerner, Denis Larsimont, Sabine Declercq, Gert Van den Eynden, Lajos Pusztai, Anna Ehinger, Wentao Yang, Khalid AbdulJabbar, Yinyin Yuan, Rajendra Singh, Crispin T. Hiley, Maise Al Bakir, Alexander J. Lazar, Stephen P. Naber, Stephan Wienert, Miluska Castillo, Giuseppe Curigliano, Maria Vittoria Dieci, Fabrice André, Charles Swanton, Jorge S. Reis‐Filho, Joseph A. Sparano, Eva Balslev, I‐Chun Chen, Elisabeth Ida Specht Stovgaard, Katherine L. Pogue–Geile, Kim Blenman, Frédérique Penault–Llorca, Stuart J. Schnitt, Sunil R. Lakhani, Anne Vincent‐Salomon, Federico Rojo, Jeremy Braybrooke, Matthew G. Hanna, María Teresa Soler-Monsó, Daniel Bethmann, Carlos Castaneda, Karen Willard‐Gallo, Ashish Sharma, Huang‐Chun Lien, Susan Fineberg, Jeppe Thagaard, Laura Comerma, Paula I. González-Ericsson, Edi Brogi, Sherene Loi, Joel Saltz, Frederick Klaushen, Lee Cooper, Mohamed Amgad, David Moore, Roberto Salgado, the International Immuno-Oncology Biomarker Working Group, Aini Hyytiäinen, Akira I. Hida, Alastair Thompson, Alexis Lefevre, Allen M. Gown, Amy Lo and 156 more - npj Breast Cancer 2020 cited by 206

  9. A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

    Authors: Torsten O. Nielsen, Joel S. Parker, Samuel Leung, D. Voduc, Mark Ebbert, Tammi L. Vickery, Sherri R. Davies, Jacqueline Snider, Inge J. Stijleman, Jerry P. Reed, Maggie C.U. Cheang, Elaine R. Mardis, Charles M. Perou, Philip S. Bernard, Matthew J. Ellis - Clinical Cancer Research 2010 cited by 824

  10. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial

    Authors: Stephen Johnston, Shannon Puhalla, Duncan Wheatley, Alistair Ring, Peter Barry, Chris Holcombe, Jean Francois Boileau, Louise Provencher, André Robidoux, Mothaffar F. Rimawi, Stuart McIntosh, I. Shalaby, Robert C. Stein, Michael P. Thirlwell, David Dolling, James P. Morden, Claire Snowdon, Sophie Perry, Chester Cornman, Leona Batten, Lisa K. Jeffs, Andrew Dodson, Vera Martins, Arjun Modi, C. Kent Osborne, Katherine L. Pogue–Geile, Maggie C.U. Cheang, Norman Wolmark, Thomas B. Julian, Kate Fisher, Mairead MacKenzie, Maggie Wilcox, Cynthia Huang Bartlett, María Koehler, Mitch Dowsett, Judith M. Bliss, Samuel A. Jacobs - Journal of Clinical Oncology 2018 cited by 235

  11. Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer

    Authors: Aleix Prat, Maggie C.U. Cheang, Miguel Martín, Joel S. Parker, Eva Carrasco, Rosalía Caballero, Scott Tyldesley, Karen A. Gelmon, Philip S. Bernard, Torsten O. Nielsen, Charles M. Perou - Journal of Clinical Oncology 2012 cited by 590

  12. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

    Authors: Torsten O. Nielsen, Forrest D. Hsu, Kristin C. Jensen, Maggie C.U. Cheang, Gamze Karaca, Zhiyuan Hu, Tina Hernandez‐Boussard, Chad Livasy, Dave Cowan, Lynn G. Dressler, Lars A. Akslen, Joseph Ragaz, Allen M. Gown, C. Blake Gilks, Matt van de Rijn, Charles M. Perou - Clinical Cancer Research 2004 cited by 2,657

  13. Breast Cancer Subtypes and the Risk of Local and Regional Relapse

    Authors: K. David Voduc, Maggie C.U. Cheang, Scott Tyldesley, Karen Gelmon, Torsten O. Nielsen, Hagen F. Kennecke - Journal of Clinical Oncology 2010 cited by 1,242

  14. Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

    Authors: Maggie C.U. Cheang, Miguel Martín, Torsten O. Nielsen, Aleix Prat, David Voduc, Álvaro Rodríguez-Lescure, Amparo Ruı́z, Stephen Chia, Lois E. Shepherd, Manuel Ruíz‐Borrego, Lourdes Calvo, Emilio Alba, Eva Carrasco, Rosalía Caballero, Dongsheng Tu, Kathleen I. Pritchard, Mark N. Levine, Vivien Bramwell, Joel S. Parker, Philip S. Bernard, Matthew J. Ellis, Charles M. Perou, Angelo Di Leo, Lisa A. Carey - The Oncologist 2015 cited by 198

  15. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

    Authors: Elizabeth Harvey-Jones, Maya Raghunandan, Luisa Robbez‐Masson, Lorena Magraner-Pardo, Thanussuyah Alaguthurai, Arielle Yablonovitch, Jennifer Yen, Hui Xiao, Rachel Brough, Jessica Frankum, Fei Song, Jason Yeung, Thierry Savy, Abha Gulati, J. Alexander, Harriet Kemp, Chris Starling, Asha Konde, Rebecca Marlow, Maggie C.U. Cheang, Paula Proszek, Michael Hubank, Muyan Cai, J. Trendell, Ruifang Lu, Raffaella Liccardo, N. Ravindran, Alba Llop‐Guevara, O. Rodriguez, Judith Balmañà, Natalia Lukashchuk, Michael O. Dorschner, Leylah Drusbosky, Ioannis Roxanis, Violeta Serra, Syed Haider, Stephen J. Pettitt, Christopher J. Lord, Andrew Tutt - Annals of Oncology 2024 cited by 71

  16. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

    Authors: Fiona M. Blows, Kristy Driver, Marjanka K. Schmidt, Annegien Broeks, Flora E. van Leeuwen, Jelle Wesseling, Maggie C.U. Cheang, Karen A. Gelmon, Torsten O. Nielsen, Carl Blomqvist, Päivi Heikkilä, Tuomas Heikkinen, Heli Nevanlinna, Lars A. Akslen, Louis R. Bégin, William D. Foulkes, Fergus J. Couch, Xianshu Wang, Vicky Cafourek, Janet E. Olson, Laura Baglietto, Graham G. Giles, Gianluca Severi, Catriona McLean, Melissa C. Southey, Emad A. Rakha, Andrew R. Green, Ian O. Ellis, Mark E. Sherman, Jolanta Lissowska, William F. Anderson, Angela Cox, Simon S. Cross, Malcolm Reed, Elena Provenzano, Sarah‐Jane Dawson, Alison M. Dunning, Manjeet K. Humphreys, Douglas F. Easton, Montserrat García‐Closas, Carlos Caldas, Paul D.P. Pharoah, David G. Huntsman - PLoS Medicine 2010 cited by 1,150

  17. Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer

    Authors: Jeppe Thagaard, Glenn Broeckx, David B. Page, Chowdhury Arif Jahangir, Sara Verbandt, Zuzana Kos, Rajarsi Gupta, Reena Khiroya, Khalid AbdulJabbar, Gabriela Acosta Haab, Balázs Ács, Güray Aktürk, Jonas S. Almeida, Isabel Alvarado‐Cabrero, Mohamed Amgad, Farid Azmoudeh Ardalan, Sunil Badve, Nurkhairul Bariyah Baharun, Eva Balslev, Enrique Bellolio, Vydehi Bheemaraju, Kim RM Blenman, Luciana Botinelly Mendonça Fujimoto, Najat Bouchmaa, Octavio Burgues, Alexandros Hardas, Maggie C.U. Cheang, Francesco Ciompi, Lee Cooper, An Coosemans, Germán Corredor, Anders Bjorholm Dahl, Flávio Luis Dantas Portela, Frederik Deman, Sandra Demaria, Johan Doré Hansen, Sarah Dudgeon, Thomas Ebstrup, Mahmoud Elghazawy, Claudio Fernandez‐Martín, Stephen B. Fox, William M. Gallagher, Jennifer M. Giltnane, Sacha Gnjatic, Paula I. González-Ericsson, Anita Grigoriadis, Niels Halama, Matthew G Hanna, Aparna Harbhajanka, Steven N. Hart, Johan Hartman, Søren Hauberg, Stephen M. Hewitt, Akira I. Hida, Hugo M. Horlings, Zaheed Husain, Evangelos Hytopoulos, Sheeba Irshad, Emiel A. M. Janssen, Mohamed M. Kahila, Tatsuki R. Kataoka, Kosuke Kawaguchi, Kharidehal Durga, Andrey Khramtsov, Umay Kiraz, Pawan Kirtani, Liudmila L. Kodach, Konstanty Korski, Anikó Kovács, Anne‐Vibeke Lænkholm, Corinna Lang‐Schwarz, Denis Larsimont, Jochen K. Lennerz, Marvin Lerousseau, Xiaoxian Li, Amy Ly, Anant Madabhushi, Sai Maley, Vidya Manur Narasimhamurthy, Douglas K. Marks, Elizabeth S. McDonald, Ravi Mehrotra, Stefan Michiels, Fayyaz Minhas, Shachi Mittal, David A. Moore, Shamim Mushtaq, Nighat Hussain, Thomas Papathomas, Frédérique Penault‐Llorca, Rashindrie Perera, Christopher J. Pinard, Juan Carlos Pinto‐Cardenas, Giancarlo Pruneri, Lajos Pusztai, Arman Rahman, Nasir Rajpoot, Bernardo L. Rapoport, Tilman T. Rau, Jorge S. Reis‐Filho and 42 more - The Journal of Pathology 2023 cited by 52

  18. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

    Authors: Lisa A. Carey, Donald A. Berry, Constance Cirrincione, William T. Barry, Brandelyn N. Pitcher, Lyndsay N. Harris, David W. Ollila, Ian E. Krop, N. Lynn Henry, Douglas Weckstein, Carey K. Anders, Baljit Singh, Katherine A. Hoadley, Michael D. Iglesia, Maggie C.U. Cheang, Charles M. Perou, Eric P. Winer, Clifford A. Hudis - Journal of Clinical Oncology 2015 cited by 437

  19. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler

    Authors: Helga Bergholtz, Jodi M. Carter, Alessandra Cesano, Maggie C.U. Cheang, S. Church, Prajan Divakar, Christopher A. Fuhrman, Shom Goel, Jingjing Gong, Jennifer L. Guerriero, Margaret L. Hoang, E. Shelley Hwang, Hellen Kuasne, Jinho Lee, Yan Liang, Elizabeth A. Mittendorf, Jessica Perez, Aleix Prat, Lajos Pusztai, Jason Reeves, Yasser Riazalhosseini, Jennifer K. Richer, Özgür Şahin, Hiromi Sato, Ilana Schlam, Thérese Sørlie, Daniel G. Stover, Sandra M. Swain, Alexander Swarbrick, E. Aubrey Thompson, Sara M. Tolaney, Sarah H. Warren - Cancers 2021 cited by 97

  20. Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer

    Authors: David B. Page, Glenn Broeckx, Chowdhury Arif Jahangir, Sara Verbandt, Rajarsi Gupta, Jeppe Thagaard, Reena Khiroya, Zuzana Kos, Khalid AbdulJabbar, Gabriela Acosta Haab, Balázs Ács, Güray Aktürk, Jonas S. Almeida, Isabel Alvarado‐Cabrero, Farid Azmoudeh Ardalan, Sunil V. Badve, Nurkhairul Bariyah Baharun, Enrique Bellolio, Vydehi Bheemaraju, Kim RM Blenman, Luciana Botinelly Mendonça Fujimoto, Najat Bouchmaa, Octavio Burgues, Maggie C.U. Cheang, Francesco Ciompi, Lee Cooper, An Coosemans, Germán Corredor, Flávio Luis Dantas Portela, Frederik Deman, Sandra Demaria, Sarah Dudgeon, Mahmoud Elghazawy, Scott Ely, Claudio Fernandez‐Martín, Susan Fineberg, Stephen B. Fox, William M. Gallagher, Jennifer M. Giltnane, Sacha Gnjatic, Paula I. González-Ericsson, Anita Grigoriadis, Niels Halama, Matthew G Hanna, Aparna Harbhajanka, Alexandros Hardas, Steven N. Hart, Johan Hartman, Stephen M. Hewitt, Akira I. Hida, Hugo M. Horlings, Zaheed Husain, Evangelos Hytopoulos, Sheeba Irshad, Emiel A. M. Janssen, Mohamed Kahila, Tatsuki R. Kataoka, Kosuke Kawaguchi, Kharidehal Durga, Andrey Khramtsov, Umay Kiraz, Pawan Kirtani, Liudmila L. Kodach, Konstanty Korski, Anikó Kovács, Anne‐Vibeke Lænkholm, Corinna Lang‐Schwarz, Denis Larsimont, Jochen K. Lennerz, Marvin Lerousseau, Xiaoxian Li, Amy Ly, Anant Madabhushi, Sai Maley, Vidya Manur Narasimhamurthy, Douglas K. Marks, Elizabeth S. McDonald, Ravi Mehrotra, Stefan Michiels, Fayyaz Minhas, Shachi Mittal, David Moore, Shamim Mushtaq, Nighat Hussain, Thomas Papathomas, Frédérique Penault‐Llorca, Rashindrie Perera, Christopher J. Pinard, Juan Carlos Pinto‐Cardenas, Giancarlo Pruneri, Lajos Pusztai, Arman Rahman, Nasir Rajpoot, Bernardo L. Rapoport, Tilman T. Rau, Jorge S. Reis‐Filho, Joana Ribeiro, David L. Rimm, Anne Vincent‐Salomon, Manuel Salto‐Tellez and 34 more - The Journal of Pathology 2023 cited by 49

  21. Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

    Authors: Maggie C.U. Cheang, C. K. Anders, A. Prat, B. Adamo, L. A. Carey, C. M. Perou - The Oncologist 2013 cited by 546

  22. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

    Authors: The I-SPY 1 TRIAL Investigators, Laura J. Esserman, Donald A. Berry, Maggie C.U. Cheang, Christina Yau, Charles M. Perou, Lisa A. Carey, Angela DeMichele, Joe W. Gray, Kathleen Conway‐Dorsey, Marc E. Lenburg, Meredith Buxton, Sarah Davis, Laura J. van’t Veer, Clifford A. Hudis, Koei Chin, Denise M. Wolf, Helen Krontiras, Leslie L. Montgomery, Debu Tripathy, Constance D. Lehman, Minetta C. Liu, Olufunmilayo I. Olopade, Hope S. Rugo, John T. Carpenter, Chad Livasy, Lynn G. Dressler, David C. Chhieng, Baljit Singh, Carolyn Mies, Joseph T. Rabban, Yunni-Yi Chen, Dilip D. Giri, Alfred Au, Nola M. Hylton - Breast Cancer Research and Treatment 2011 cited by 376

  23. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

    Authors: Maggie C.U. Cheang, David Voduc, Chris Bajdik, Samuel Leung, Steven McKinney, Stephen Chia, Charles M. Perou, Torsten O. Nielsen - Clinical Cancer Research 2008 cited by 1,188

  24. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer

    Authors: Fara Brasó‐Maristany, Simone Filosto, Steven Catchpole, Rebecca Marlow, Jelmar Quist, Erika Francesch-Domenech, Darren A Plumb, Leila Zakka, Patrycja Gazińska, Gianmaria Liccardi, Pascal Meier, Albert Gris‐Oliver, Maggie C.U. Cheang, Anna Perdrix-Rosell, Manar Shafat, Elodie Noël, Nirmesh Patel, Kristen McEachern, Maurizio Scaltriti, Pau Castel, Farzana Noor, Richard Buus, Sumi Mathew, Johnathan Watkins, Violeta Serra, Pierfrancesco Marra, Anita Grigoriadis, Andrew Tutt - Nature Medicine 2016 cited by 245